WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 591253
CAS#: 5696-09-3
Description: Proxazole is a drug used for functional gastrointestinal disorders.
MedKoo Cat#: 591253
Name: Proxazole
CAS#: 5696-09-3
Chemical Formula: C17H25N3O
Exact Mass: 287.1998
Molecular Weight: 287.41
Elemental Analysis: C, 71.04; H, 8.77; N, 14.62; O, 5.57
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Proxazole; Aerbron;
IUPAC/Chemical Name: 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-
InChi Key: OLTAWOVKGWWERU-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H25N3O/c1-4-15(14-10-8-7-9-11-14)17-18-16(21-19-17)12-13-20(5-2)6-3/h7-11,15H,4-6,12-13H2,1-3H3
SMILES Code: CCC(C1=NOC(CCN(CC)CC)=N1)C2=CC=CC=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 287.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Gaetani E, Laureri C, Vitto M. GC-ITD detection and quantitative analysis of proxazole in cows' plasma and milk. J Pharm Biomed Anal. 1995 Mar;13(3):335-7. PubMed PMID: 7619896.
2: Wainer E, Wittenberg C, Boner G, Rosenfeld JB. The effects of proxazole on renal function in chronic renal failure. Arzneimittelforschung. 1981;31(3):527-8. PubMed PMID: 7194677.
3: Vangelista A, Nanni Costa A, Buscaroli A, Raggiotto G. [Controlled study of of the long-term effects of the prolonged administration of proxazole in patients with chronic renal insufficiency]. G Clin Med. 1980 Nov;61(11):831-43. Italian. PubMed PMID: 7016648.
4: Heiss WD. [Pharmacologic modification of the circulation in the brain]. Bull Schweiz Akad Med Wiss. 1980 Apr;36(1-3):183-207. Review. German. PubMed PMID: 6107132.
5: Saponaro A, Russo R, Tomei F, Giordano M, Dragagna G, Barbato G. [Effects of proxazole on patients with obliterating arteriopathy of the lower limbs]. Clin Ter. 1979 Dec 31;91(6):585-92. Italian. PubMed PMID: 544162.
6: Painvain E, Rusticali B. [Comparative study of the effects of proxazole on the duration of the dilatation period in labor]. Patol Clin Ostet Ginecol. 1979 Nov-Dec;7(6):407-11. Italian. PubMed PMID: 527762.
7: Amato G, Benedetti A, Masiero MG, Migliorini A. [Controlled study of the effects of proxazole in labor]. Minerva Ginecol. 1979 Sep;31(9):693-7. Italian. PubMed PMID: 537714.
8: Sprocato S, Molinaroli P, Mazzocchi F, Romitti M. [Treatment of acute renal insufficiency in intensive care. Current perspectives with TPA and proxazole]. Minerva Anestesiol. 1979 Sep;45(9):691-8. Italian. PubMed PMID: 117401.
9: Rondinelli M, Suma V, Casara D, Zonzin G. Effects of the treatment with proxazole citrate on the utero-placental blood flow of patients affected by EPH-gestosis. Bibl Anat. 1979;(18):274-6. PubMed PMID: 496846.
10: Heiss WD, Podreka I. Assessment of pharmacological effects on cerebral blood flow. Eur Neurol. 1978;17 Suppl 1:135-43. PubMed PMID: 753629.
11: Maselli G, Delli Colli R, Donadio C. [Proxazole citrate in labor]. Patol Clin Ostet Ginecol. 1977 Jul-Aug;5(4):200-8. Italian. PubMed PMID: 606606.
12: De Nigris C, Manenti E. [Proxazole in preparatory treatment in labor]. Minerva Ginecol. 1977 Jul-Aug;29(7-8):599-605. Italian. PubMed PMID: 563028.
13: Polacco V, Piccolomini A, Masin G, Scivoli L, Suma V. [Effects of proxazole on spastic dystocia of the uterine cervix]. Riv Ital Ginecol. 1977 Jan-Apr;58(1-2):71-80. Italian. PubMed PMID: 617874.
14: Esposito G, De Gregorio M. Proxazole in cerebrovascular insufficiency. A controlled clinical trial. Arzneimittelforschung. 1974 Oct;24(10):1692-6. PubMed PMID: 4611436.
15: Mainieri L. [Clinical experiences with proxazole in the therapy of cerebrovascular diseases]. Minerva Med. 1974 May 26;65(40):2281-6. Italian. PubMed PMID: 4422429.
16: Heiss WD, Prosenz P, Bruck J. Effect of proxazole on total and regional cerebral blood flow. Arzneimittelforschung. 1973 Jun;23(6):772-5. PubMed PMID: 4579949.
17: Calabrese L, Macchini M. Study on the action of proxazole citrate on gastric blood supply. Endoscopic findings in elderly patients. Arzneimittelforschung. 1972 Apr;22(4):763-8. PubMed PMID: 5068257.
18: Burberi S, Silvestrini B. Preventive action of proxazole in experimentally induced renal hypertension in rats. Jpn J Pharmacol. 1971 Jun;21(3):283-91. PubMed PMID: 5314719.
19: De Feo G, Giannangeli M, Piccinelli D, Sale P. [Separation and pharmacological study of 2 anantiomers of proxazole]. Farmaco Sci. 1971 Apr;26(4):370-6. Italian. PubMed PMID: 5559995.
20: Mioli V, Albertazzi A, Vangelista A, Bortolotti GC, Bonomini V. [Further studies on the effect of proxazole on the human kidney]. Policlinico Med. 1971 Jan-Feb;78(1):25-47. Italian. PubMed PMID: 5088668.
